GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SK Bioscience Co Ltd (XKRX:302440) » Definitions » Equity-to-Asset

SK Bioscience Co (XKRX:302440) Equity-to-Asset : 0.88 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is SK Bioscience Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. SK Bioscience Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₩1,691,536 Mil. SK Bioscience Co's Total Assets for the quarter that ended in Mar. 2024 was ₩1,918,053 Mil. Therefore, SK Bioscience Co's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.88.

The historical rank and industry rank for SK Bioscience Co's Equity-to-Asset or its related term are showing as below:

XKRX:302440' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.47   Med: 0.75   Max: 0.92
Current: 0.88

During the past 6 years, the highest Equity to Asset Ratio of SK Bioscience Co was 0.92. The lowest was 0.47. And the median was 0.75.

XKRX:302440's Equity-to-Asset is ranked better than
81.14% of 1559 companies
in the Biotechnology industry
Industry Median: 0.67 vs XKRX:302440: 0.88

SK Bioscience Co Equity-to-Asset Historical Data

The historical data trend for SK Bioscience Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SK Bioscience Co Equity-to-Asset Chart

SK Bioscience Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial 0.58 0.47 0.76 0.81 0.92

SK Bioscience Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.85 0.87 0.90 0.92 0.88

Competitive Comparison of SK Bioscience Co's Equity-to-Asset

For the Biotechnology subindustry, SK Bioscience Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SK Bioscience Co's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SK Bioscience Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where SK Bioscience Co's Equity-to-Asset falls into.



SK Bioscience Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

SK Bioscience Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=1703855.316/1852439.18
=0.92

SK Bioscience Co's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=1691536.079/1918053.371
=0.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SK Bioscience Co  (XKRX:302440) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


SK Bioscience Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of SK Bioscience Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


SK Bioscience Co (XKRX:302440) Business Description

Traded in Other Exchanges
N/A
Address
310, Pangyo-ro, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13494
SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and developing of vaccine. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further it has several other vaccines under development and clinical trials including recombinant rotavirus vaccine. In addition, the development of new typhoid conjugate vaccine and innovative pneumococcal vaccine is ongoing in collaboration with external partners.

SK Bioscience Co (XKRX:302440) Headlines

No Headlines